Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection.
The novel coronavirus, SARS-CoV-2 that causes COVID-19 has resulted in the death of nearly 4 million people within the last 18 months. While preventive vaccination, and monoclonal antibody therapies have been rapidly developed and deployed, early in the pandemic the use of COVID-19 convalescent plas...
Main Authors: | Natasha M Clark, Sanath Kumar Janaka, William Hartman, Susan Stramer, Erin Goodhue, John Weiss, David T Evans, Joseph P Connor |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2022-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0257930 |
Similar Items
-
Transient IgA, steady IgG?
by: Berthold, DL, et al.
Published: (2020) -
A Case of IgG and IgA Anti-Laminin-332 Antibody-Positive Mucous Membrane Pemphigoid with IgG and IgA Anti-Envoplakin and Anti-Periplakin Antibodies
by: Yoshiaki Matsushima, et al.
Published: (2022-08-01) -
Linear IgA disease: the IgA and IgG response to the epidermal antigens demonstrates that intermolecular epitope spreading is associated with IgA rather than IgG antibodies, and is more common in adults.
by: Allen, J, et al.
Published: (2003) -
Linear IgA and IgG bullous dermatosis
by: Karina de Almeida Pinto Fernandes, et al.
Published: (2016-10-01) -
Lower Levels of ABO Anti-A and Anti-B of IgM, IgG and IgA Isotypes in the Serum but Not the Saliva of COVID-19 Convalescents
by: Eva M. Matzhold, et al.
Published: (2022-08-01)